Qualtix Stock Brief
AbbVie Inc. (ABBV) stock analysis: business quality, valuation, and entry timing
AbbVie is a pharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics. How well newer medicines replace revenue from older products as patents expire is the main question behind its business quality. Public Qualtix model snapshot from 2026-10-26 for ABBV: business quality 63/100, a mixed model reading and valuation Expensive. Today's verdict and Entry Timing are shown after a free sign-in.
Qualtix evaluates ABBV with a rules-based model that separates business quality, valuation, entry timing, red flags, and data confidence. The model scores first; AI explanations and the full Clean Brief help explain the result afterward.
Coverage note: Qualtix can analyze supported US stocks when SEC/FMP filing data is available. The 1,000+ stock universe refers to the daily screener used for discovery, not the full analysis limit.
ABBV public evidence metrics from the latest validated Qualtix snapshot
| Metric | Value | Why it matters | Source |
|---|---|---|---|
| Revenue growth | 4.7% | 3-year revenue CAGR | FMP, computed |
| FCF margin | 28.3% | Free cash flow divided by revenue | FMP, computed |
| Operating margin | 29.3% | Profitability margin | FMP, computed |
| Gross margin | 71.5% | Revenue retained after direct costs | FMP, computed |
| Return on capital (pre-tax) | 29.1% | Operating profit before tax, divided by equity plus debt | FMP, computed |
| Cash and debt | Cash $6.6B / Debt $70.8B | Balance-sheet context | FMP, reported |
| TTM P/E | 80.4x | Price to trailing earnings | FMP, computed |
| Market cap | $506.8B | Company size context | FMP, reported |
Qualtix view
- Business quality: 63/100, a mixed model reading.
- Valuation is currently labeled Expensive, so the stock needs stronger business evidence or a better price to improve the setup.
Today's verdict
- Today's model verdict and Entry Timing for ABBV update every market day and are shown after a free sign-in.
Data and snapshot dates
- Model snapshot date: 2026-10-26.
- Financial data through: 2026-06-30.
- Scored by the current Qualtix model.
- Data-confidence status: high.
What supports the current view
- Beta of 0.28 suggests lower market sensitivity than higher-beta alternatives.
What weakens the current view
- Business quality remains below the model's stronger-company threshold (63/100).
- Valuation is currently labeled Expensive, so price still matters.
What changed
- Business Quality was unchanged from the previous snapshot.
What to research next
- Start with the weaker Business Quality signal (63/100): review revenue durability, margins, cash generation, and balance-sheet pressure.
- Compare ABBV's Expensive valuation with sector peers and ask what growth or margin evidence would justify the premium.
- Compare ABBV with LLY and MRK to see whether the model edge is company-specific or sector-wide.
Follow Qualtix on X, TikTok, LinkedIn, YouTube.
Qualtix is for research and education only. It is not financial advice.